The US generics business is under severe structural pricing pressure, with no near-term catalyst for reversal. Watch for further erosion in upcoming quarters and the pace of new product launches (79 ANDAs pending, 24 first-to-file). The semaglutide quality issue may signal broader manufacturing risk; monitor FDA inspection outcomes at the Biologics Hyderabad facility (7 observations in June 2026). Non-US growth is strong but insufficient to offset US headwinds. The new auditor appointment (Deloitte) is a governance change worth noting but not immediately material.
Price Chart
Executive Summary
Dr. Reddy's Q1 FY2027 results were sharply below prior year: revenue fell 6% YoY to Rs.80,705M, operating profit collapsed 78% to Rs.3,784M, and EPS dropped 69% to Rs.5.32. The US generics business was the primary drag, with North America revenue down 35% (41% in USD) due to price erosion and volume declines. Gross margin contracted 10.4pp to 46.5%, further pressured by a Rs.2,397M semaglutide inventory write-down. Growth in India (+17%), Emerging Markets (+31%), and Russia (+28%) partially offset the US decline but could not prevent a 69% profit plunge.
Key Facts
- Revenue decreased 6% YoY to Rs.80,705M (Q1 FY2026: Rs.85,452M)
- North America (US+Canada) revenue fell 35% to Rs.22,048M; in USD terms down 41%
- Gross profit margin collapsed from 56.9% to 46.5%
- Operating profit (results from operating activities) down 78% to Rs.3,784M
- Net profit attributable to parent down 69% to Rs.4,435M; basic EPS Rs.5.32 vs Rs.17.04
- Rs.2,397M provision for semaglutide inventory write-down due to API quality issue
- SG&A expenses rose 12% YoY to Rs.28,820M (35.7% of revenue vs 30.0%)
- India revenue +17%, Emerging Markets +31%, Russia +28% (INR terms)
- Board appointed Deloitte Haskins & Sells as new independent auditor
- Proposed dividend of Rs.8 per share (subject to shareholder approval)
Financial Impact
Revenue decline of ~Rs.4,747M ($50M) and net profit decline of ~Rs.9,743M ($103M) YoY; gross margin compression of 10.4pp represents ~Rs.11,087M in lost gross profit
Risk Factors
- Continued US generic price erosion and volume declines
- FDA regulatory actions or warning letters following June 2026 inspection
- Additional costs or liabilities from semaglutide quality issue
- Geopolitical risks in Russia/Ukraine (28% of revenue from Russia)
- Ranitidine litigation settlement costs (Illinois cases pending)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (RDY) — Batch item 1 | 0001575872-26-000522 |
| Exhibit: ex991_1.htm | 0001575872-26-000522 |
| Document: 0001575872-26-000522-index-headers.html | 0001575872-26-000522 |
| Document: 0001575872-26-000522-index.html | 0001575872-26-000522 |
| Document: 0001575872-26-000522.txt | 0001575872-26-000522 |
| 6-K Filing (RDY) — Batch item 6 | 0001575872-26-000522 |
| Exhibit: ex991_1.htm | 0001575872-26-000522 |
| Document: 0001575872-26-000522-index-headers.html | 0001575872-26-000522 |
| Document: 0001575872-26-000522-index.html | 0001575872-26-000522 |
| Document: 0001575872-26-000522.txt | 0001575872-26-000522 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $11.91 $11.55 | ▼ −3.02% | ▼ −2.56% | $12.25 (+2.85%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Aug 26, 2026 5w ago | 6-K | $12.22 $12.16 | ▼ −0.49% | ▼ −1.15% | $12.25 (+0.25%) |
Aug 17, 2026 6w ago | 6-K | $12.11 $12.15 | ▲ +0.33% | ▲ +1.01% | $12.25 (+1.16%) |
Aug 13, 2026 7w ago | 6-K | $12.42 $12.27 | ▼ −1.21% | ▼ −1.01% | $12.25 (−1.37%) |
Aug 10, 2026 7w ago | 6-K | $12.15 $12.45 | ▲ +2.47% | ▲ +2.79% | $12.25 (+0.82%) |
Aug 3, 2026 8w ago | 6-K | $12.07 $12.10 | ▲ +0.25% | ▼ −1.55% | $12.25 (+1.49%) |
Jul 29, 2026 9w ago | 6-K | $11.76 $11.83 | ▲ +0.60% | ▼ −1.08% | $12.25 (+4.17%) |
Jul 23, 2026 10w ago | 6-K | $11.80 $11.79 | ▼ −0.08% | ▼ −0.19% | $12.25 (+3.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access